Sensorineural Hearing Loss Screening - 華聯生物科技

Sensorineural Hearing Loss Screening

In collaboration with Dr. Ko Tsang-Ming’s lab, Phalanx Biotech developed a test covering more than 90% of the four common hearing impairment-related genes and 361 alleles. It is used with conventional physical examination to provide parents with a more complete result.

The importance of Sensorineural Hearing Loss Screening

Hearing impairment is the most common congenital defect in newborns. Hearing plays a crucial part in the cognitive and language development of babies. Congenital hearing impairment is also a key factor of language learning, social communication and intellectual development.

Tested loci
Children with hearing impairment

Congenital hearing impairment Common predisposing gene of sensory hearing impairment

Phalanx Biotech’s “Sensorineural Hearing Loss Screening” covers more than 90% of common mutated loci related to hearing (up to 361), while other providers offering an average of 6 loci. Phalanx Biotech is able to provide more complete hearing gene screening.


  • All newborns
  • Concerned of neonatal hearing impairment
  • Newborns from a family of two or more diagnosed with sensory hearing impairment

Screening procedure


Genetic consultation and education


Writing informed consent for neonatal gene screening


Collect blood sample from the newborn’s heel


Gene analysis report

This screening is a collaboration project by Phalanx Biotech and GenePhile Bioscience Laboratory (Ko’s Obstetrics and Gynecology Clinic). All tests are carried out by GenePhile Bioscience Laboratory.

Contact Us